1 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among others: The forward-looking statements contained in this release are based on Merit management's current expectations and assumptions regarding future events or outcomes. If underlying expectations or assumption ...

TransMedics Q4 2025 Performance Highlights February 24, 2026 2 TMDX Q4 2025 Performance – Key Highlights Product Revenue $100.4M 33.9% Y/Y Growth 14.5% Q/Q Growth 1 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements. These forward-looking statements address various matters, including, among other things, future results and events, including financial guidance and projected estimates, and other statements that are predictive in nature. Investors are cau ...

Q4 2025 FINANCIAL RESULTS PAT MILES, CHAIRMAN & CEO | TODD KNING, EVP & CFO | FEBRUARY 24, 2026 FORWARD-LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking stateme ...

NEWBURYPORT, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported 2025 net income of $68.3 million, 15.8% higher than net income of $59.0 million for 2024. Adjusted net income grew 12.7% to $76.1 million. Net sales for the year ended December 31, 2025 were $602.8 million, 19.5% higher than 2024 sales of $504.4 million. GAAP and adjusted earnings p ...

AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025: Worldwide net sales were $826.4 million, an increase of 25.7%, or an increase of 24.7% on a constant currency basis.Base business, excluding Nevro, net sales were $726.7 million, an increase of 10.6%, or an increase of 9.4% on a constant currency basis.GAAP ...

DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2025 before the market opens on Thursday, March 5, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-04 ...

Fourth Quarter Highlights† Reported revenue of $393.9 million, up 11%Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectivelyGAAP operating margin of 13.8%, compared to 10.3% in prior year periodNon-GAAP operating margin* of 21.0%, compared to 19.6% in prior year periodGAAP EPS $0.63, up 37%Non-GAAP EPS* $1.04, up 12%Free cash flow* generation of $74.0 million, up 13% Fiscal Year 2025 Highlights† Reported revenue of $1.516 billion, up 12%Constant currency revenue* an ...

SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 & Recent Highlights Reported total revenue of $24.8 million in the fourth quarter of 2025, a 34% increase compared to the same period in 2024Delivered total revenue of ...

Pacitti said the SNS portfolio delivered “strong above market” performance in 2025, growing over 8% organically year over year. He cited strength across long-term, short-term, and neonatal enteral feeding, including support from Avanos’s “Go Direct” transition in the U.K. that was executed in the third quarter of 2025.In the quarter, Avanos reported $0.29 in adjusted diluted EPS and $28 million of adjusted EBITDA. Adjusted gross margin was 53.4% and adjusted SG&A was 39.1% of revenue. For the full year, adj ...

West Pharmaceutical Services, Inc. (NYSE:WST) is one of the 10 best life sciences stocks to buy according to hedge funds. On February 17, the governing body of West Pharmaceutical Services, Inc. (NYSE:WST) approved a new share repurchase program authorizing the buyback of up to $1 billion of its common stock. The firm highlighted that the previous repurchase program had been fully utilized ahead of its December 31, 2025, expiration. The new authorization reflects continued capital return initiatives and p ...